§
Luxuse
Patent Intelligence
Sign In
Patent EP0576898A2 successfully refreshed from Google Patents.
← Back to Patent Explorer
EP0576898A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Linear peptides

Assignee: Merck Patent GmbH
•
Filing: 1993-06-15
•
Granted: —
•
Expires: 2013-06-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to novel linear peptides of Formulae Ia - In (Ia)   H-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ib)   H-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ic)   H-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Id)   H-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ie)   H-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (If)   H-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ig)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ih)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-OH; (Ii)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-OH; (Ij)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-OH; (Ik)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-OH; (Il)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-OH; (Im)   Ac-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-OH; (In)   Ac-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-OH; wherein Ac stands for acetyl, and salts thereof. These substances inhibit, inter alia , cell adhesion.

Inventors

  • 👤 Alfred Dr. Jonczyk
  • 👤 Brundhilde Dr. Felding-Habermann
  • 👤 Guido Dr. Melzer
  • 👤 Beate Diefenbach
  • 👤 David A. Dr. Cheresh

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-10 01:55
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/06; C07K14/00; C07K14/435; C07K14/745; C07K14/75; A; A61; A61P; A61P35/00; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10; C07K14/78; A61K; A61K38/00

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 42 words
A compound of formula Ia-In (Ia) H-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ib) H-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ic)   H-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Id)   H-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ie)   H-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (If)    H-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ig)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-Tyr-OH; (Ih)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-OH; (Ii)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-OH; (Ij)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-OH; (Ik)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-OH; (Il)   H-Gly-Asp-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-OH; (Im)   Ac-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-OH; (In)   Ac-Gly-Arg-His-Asp-Leu-Leu-Val-Gly-Ala-Pro-Leu-OH; wherein Ac stands for acetyl, or a salt thereof.
Claim 2
Dependent Claim 22 words
A pharmaceutical composition comprising an amount of a compound of claim 1 effective to inhibit cell adhesion and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim 15 words
A composition according to claim 2, wherein the amount of said compound is 0.05-500 mg.
Claim 4
Dependent Claim 15 words
A composition according to claim 2, wherein the amount of said compound is 0.5-100 mg.
Claim 5
Dependent Claim 28 words
A method of treatment or prophylaxis of thrombosis, myocardial infarct, angina pectoris, apoplexy or tumors in a patient comprising administering to said patient a compound of claim 1.
Claim 6
Dependent Claim 15 words
A method of inhibiting adhesion of animal cells comprising administering a compound of claim 1.
Claim 7
Dependent Claim 14 words
A method according to claim 6, wherein said cells are somatic cells of animals.
Claim 8
Dependent Claim 14 words
A method according to claim 6, wherein said cells are cancel cells of mammals.
Claim 9
Dependent Claim 23 words
A method according to claim 5, wherein said compound is administered in a daily dosage of 0.1-2 mg per kg of body weight.
Claim 10
Dependent Claim 23 words
A method according to claim 6, wherein said compound is administered in a daily dosage of 0.1-2 mg per kg of body weight.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag